Latest Manufacturing News

Page 20 of 335
Immutep’s FY2026 filing puts the full cost of the failed TACTI-004 Phase III trial on display: a larger loss, an impaired efti asset and a manufacturing investigation that remains unresolved. The company has A$68.9 million in cash and term deposits, which it forecasts will fund operations into the first half of calendar 2028 under current plans.
Ada Torres
Ada Torres
26 Oct 2026
Structural Monitoring Systems remained profitable in the September quarter, but revenue, earnings and free cash flow all fell as aircraft maintenance delays weighed on avionics sales. The company also said Boeing’s FAA approval pathway for its 737NG structural monitoring application is taking longer than expected, with no revised completion date.
Victor Sage
Victor Sage
26 Oct 2026
Star Combo Pharma has completed a manufacturing expansion that doubles production capacity, but FY2026 revenue fell 15% and profit before tax dropped to $528,472. The company remains cash-backed and dividend-paying, while its next test is converting spare capacity into stronger OEM and Own Brands growth.
Ada Torres
Ada Torres
23 Oct 2026
Supply Network is targeting around $50 million of additional revenue in FY2027 after delivering 15.5% sales growth and expanding its Multispares network across Australia and New Zealand. The next phase includes a planned $9 million Penrith branch and further capacity upgrades, although the company has not quantified the earnings return from that investment.
Victor Sage
Victor Sage
23 Oct 2026
Saluda Medical delivered 28% FY26 revenue growth and expanded its spinal cord stimulation opportunity with CAP24, but its annual report warns that additional capital may be needed within 12 months. The ASX-listed medical device company also begins FY27 under new CEO Michael Mathias.
Victor Sage
Victor Sage
23 Oct 2026
AML3D has carried $16.8 million of orders into FY27, with its US defence expansion driving a sales pipeline above $80 million. Customer receipts rose 19% in the September quarter, while the company retained $24.42 million in cash to fund capacity expansion.
Victor Sage
Victor Sage
23 Oct 2026
dorsaVi has commercially launched its first wearable capable of analysing movement and delivering feedback directly on-device, while its RRAM chip program moves into fabrication and testing. The progress comes alongside a post-quarter A$3.0 million capital raising, against quarter-end cash of $1.12 million and operating cash outflow of about $996,000.
Sophie Babbage
Sophie Babbage
23 Oct 2026
Arovella has released two clinical batches of its off-the-shelf CAR-iNKT therapy, activated two trial sites and begun screening patients ahead of expected first dosing in October. The biotech ended September with A$11.6 million in cash, rising to about A$15.63 million pro forma after an R&D rebate.
Ada Torres
Ada Torres
23 Oct 2026
BluGlass has expanded its customer-funded GaN laser programs with a A$1.4 million Uviquity contract and a new A$286,000 photonics collaboration. But its A$8 million facility is fully drawn, carries 16.5% interest and leaves reported funding coverage at 2.8 quarters.
Victor Sage
Victor Sage
23 Oct 2026
Argent BioPharma ended the September quarter with just A$11,000 in cash after A$734,000 of operating outflows, despite retaining A$7.4 million of unused convertible financing capacity. The company is simultaneously expanding its commercial portfolio through NLC antiviral rights and a CannEpil veterinary programme.
Victor Sage
Victor Sage
23 Oct 2026
Energy World has completed a major delivery milestone in its US$350 million turbine sale, receiving US$50 million and securing a further US$265 million in escrow. Most of the remaining proceeds still depend on inspection, refurbishment costs and final completion in early 2027.
Maxwell Dee
Maxwell Dee
22 Oct 2026
Jatcorp’s revenue rose 23% to $38.9 million in FY2026, but weaker margins, negative operating cash flow and a material going-concern uncertainty leave the nutritional products maker’s recovery unfinished. The company ended the year with $5.6 million in cash after a $4.2 million entitlement offer, while Neurio trademark litigation in China remains unresolved.
Victor Sage
Victor Sage
22 Oct 2026

Browse the archive

Full archive